BMS Speeding Six More Programs Into Late-Stage R&D

Registrational Candidates Will Double Over 18 Months

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

With big losses of exclusivity later in this decade, Bristol is looking to boost the number of products in its portfolio by 2030 even beyond the $35bn-plus in new revenue it already expects to bring in.

Bristol Myers Squibb Company is in a race against the clock as multiple blockbusters – including top-sellers Eliquis (apixaban) and Opdivo (nivolumab) – face losses of exclusivity over the next five years. The big pharma has nine new products that are expected to generate a combined $25bn-plus in sales by 2030 and six drug candidates in registrational trials that could add another $10bn or more in peak sales. And now the company will move another six programs into registrational trials during the next 18 months.

Key Takeaways

  • BMS is preparing for five products that altogether generated $27.8bn in 2022 sales to lose patent exclusivity between 2024 and 2028.

Bristol revealed its plans to advance those assets into later-stage clinical trials on 14 September when it hosted an R&D...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains